AbbVie Lifts Outlook, Eyes Parkinson’s Assets As Next Growth Frontier

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23. Global net revenues from the immunology portfolio were $7.63 billion, up 9.5% (+9.2% on an operational basis), including-Skyrizi sales increased 62.2% (+61.8%) to $4.42 billion; Rinvoq s
July 31, 2025